Substantial changes in disease progression were observed after a single oral dose of tivoxavir marboxil in the ferret model of bird flu using the A/Texas/37/2024 H5N1 virus isolated from an infected ...
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, ...
NEWTOWN, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ...
NEWTON, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target ...
Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent suppression of resistant viruses and Phase 1 data Full ...
Sanofi, a global leader in biopharmaceutical innovation, recently hosted a hybrid symposium titled "Safeguarding High-Risk Groups: The Importance of Flu Prevention and Effective Communication." The ...
Solubility is fundamental in successfully developing all classes of therapeutic biopolymers. Contact with stressors related to mechanical stirring or changes in buffer conditions may cause ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results